Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Shows Limited Progress In Managing DTC Workload, GAO Tells House Panel

This article was originally published in The Pink Sheet Daily

Executive Summary

House Energy and Commerce panel hearing focuses on DTC ads for Vytorin, Lipitor and Procrit.

You may also be interested in...

FDA’s Change Of Heart On Vytorin Ads

Although the campaign had been running for years with no problems, FDA instructed Merck/Schering-Plough to revise the Vytorin DTC ads even as the agency publicly affirmed the utility of the drug.

Pfizer Pulls Plug On Controversial Lipitor Ads

Congressional probe of direct-to-consumer marketing sparks firm's change of heart on anti-cholesterol drug.

Pharma DTC Spend Increasing At Twice The Rate Of Physician Promotions, GAO Finds

A Government Accountability Office report, released Dec. 14, calls for improvements in FDA’s oversight of direct-to-consumer advertising.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts